Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 5 | 2015 | 22 | 1.410 |
Why?
|
| Managed Care Programs | 6 | 2017 | 300 | 1.130 |
Why?
|
| Health Expenditures | 3 | 2014 | 72 | 0.870 |
Why?
|
| Diverticulitis, Colonic | 2 | 2014 | 8 | 0.850 |
Why?
|
| Middle Aged | 20 | 2021 | 7836 | 0.610 |
Why?
|
| Emergency Service, Hospital | 4 | 2021 | 384 | 0.600 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2018 | 42 | 0.550 |
Why?
|
| Data Collection | 3 | 2014 | 238 | 0.550 |
Why?
|
| Algorithms | 2 | 2020 | 223 | 0.540 |
Why?
|
| Febrile Neutropenia | 1 | 2017 | 3 | 0.540 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2014 | 64 | 0.520 |
Why?
|
| Retrospective Studies | 12 | 2021 | 2415 | 0.520 |
Why?
|
| Antirheumatic Agents | 3 | 2015 | 11 | 0.510 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2015 | 6 | 0.480 |
Why?
|
| Aged | 17 | 2021 | 6084 | 0.480 |
Why?
|
| Male | 19 | 2021 | 9804 | 0.480 |
Why?
|
| Asthma | 2 | 2016 | 400 | 0.470 |
Why?
|
| Female | 19 | 2021 | 12396 | 0.470 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 203 | 0.460 |
Why?
|
| Diverticulitis | 1 | 2014 | 2 | 0.450 |
Why?
|
| Humans | 22 | 2021 | 17314 | 0.450 |
Why?
|
| Electronic Health Records | 3 | 2020 | 704 | 0.440 |
Why?
|
| Inpatients | 1 | 2014 | 79 | 0.430 |
Why?
|
| Outpatients | 1 | 2014 | 101 | 0.430 |
Why?
|
| Consumer Behavior | 2 | 2004 | 28 | 0.420 |
Why?
|
| Health Care Costs | 1 | 2015 | 207 | 0.420 |
Why?
|
| Ambulatory Care | 1 | 2014 | 225 | 0.400 |
Why?
|
| Mental Health | 1 | 2014 | 169 | 0.390 |
Why?
|
| Young Adult | 8 | 2015 | 2465 | 0.390 |
Why?
|
| Adolescent | 9 | 2015 | 3538 | 0.390 |
Why?
|
| Self Report | 1 | 2014 | 257 | 0.380 |
Why?
|
| Adult | 12 | 2016 | 7500 | 0.360 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 437 | 0.340 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 381 | 0.340 |
Why?
|
| Acute Coronary Syndrome | 2 | 2021 | 17 | 0.340 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 969 | 0.320 |
Why?
|
| California | 9 | 2019 | 2311 | 0.320 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 1925 | 0.310 |
Why?
|
| Acute Disease | 3 | 2014 | 144 | 0.310 |
Why?
|
| Comorbidity | 4 | 2015 | 560 | 0.310 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2019 | 57 | 0.300 |
Why?
|
| Cohort Studies | 6 | 2020 | 2514 | 0.270 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 226 | 0.240 |
Why?
|
| United States | 6 | 2015 | 3866 | 0.240 |
Why?
|
| Drug Information Services | 1 | 2004 | 3 | 0.220 |
Why?
|
| Drug Industry | 1 | 2004 | 4 | 0.220 |
Why?
|
| Advertising as Topic | 1 | 2004 | 9 | 0.220 |
Why?
|
| Formularies as Topic | 1 | 2004 | 2 | 0.220 |
Why?
|
| Leukocytosis | 2 | 2014 | 5 | 0.210 |
Why?
|
| Abdominal Pain | 2 | 2014 | 14 | 0.210 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2004 | 23 | 0.210 |
Why?
|
| Treatment Outcome | 3 | 2018 | 1160 | 0.210 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 342 | 0.210 |
Why?
|
| Fever | 2 | 2014 | 54 | 0.210 |
Why?
|
| Critical Pathways | 1 | 2021 | 10 | 0.170 |
Why?
|
| Odds Ratio | 4 | 2015 | 640 | 0.170 |
Why?
|
| Sex Factors | 3 | 2021 | 603 | 0.170 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2020 | 2 | 0.160 |
Why?
|
| Tonsillar Neoplasms | 1 | 2020 | 2 | 0.160 |
Why?
|
| Robotic Surgical Procedures | 1 | 2020 | 8 | 0.160 |
Why?
|
| Exercise Test | 1 | 2020 | 45 | 0.160 |
Why?
|
| Urinary Bladder | 1 | 2019 | 10 | 0.160 |
Why?
|
| Hospitalization | 2 | 2017 | 804 | 0.160 |
Why?
|
| BCG Vaccine | 1 | 2019 | 8 | 0.160 |
Why?
|
| Adjuvants, Immunologic | 1 | 2019 | 16 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 56 | 0.150 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 532 | 0.150 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 58 | 0.150 |
Why?
|
| Recurrence | 2 | 2016 | 165 | 0.150 |
Why?
|
| Risk Assessment | 2 | 2021 | 1076 | 0.150 |
Why?
|
| Incidence | 3 | 2017 | 1266 | 0.150 |
Why?
|
| Disease Progression | 2 | 2016 | 259 | 0.140 |
Why?
|
| Logistic Models | 3 | 2015 | 879 | 0.140 |
Why?
|
| Mastectomy, Segmental | 1 | 2018 | 21 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2019 | 149 | 0.140 |
Why?
|
| Mastectomy | 1 | 2018 | 35 | 0.140 |
Why?
|
| Comparative Effectiveness Research | 1 | 2018 | 62 | 0.140 |
Why?
|
| Quality of Health Care | 1 | 2019 | 259 | 0.130 |
Why?
|
| Blood Cells | 1 | 2016 | 4 | 0.130 |
Why?
|
| Eosinophils | 1 | 2016 | 9 | 0.130 |
Why?
|
| Age Factors | 2 | 2019 | 878 | 0.130 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2019 | 535 | 0.130 |
Why?
|
| Population Surveillance | 2 | 2015 | 252 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 535 | 0.120 |
Why?
|
| Registries | 1 | 2018 | 460 | 0.120 |
Why?
|
| Medication Adherence | 2 | 2015 | 235 | 0.120 |
Why?
|
| Etanercept | 1 | 2015 | 4 | 0.120 |
Why?
|
| Adalimumab | 1 | 2015 | 4 | 0.120 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 86 | 0.120 |
Why?
|
| Hip Fractures | 1 | 2015 | 71 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2014 | 211 | 0.110 |
Why?
|
| Patient Preference | 1 | 2014 | 49 | 0.100 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2013 | 3 | 0.100 |
Why?
|
| Bupropion | 1 | 2013 | 9 | 0.100 |
Why?
|
| Nicotinic Agonists | 1 | 2013 | 15 | 0.100 |
Why?
|
| Quinoxalines | 1 | 2013 | 12 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 165 | 0.100 |
Why?
|
| Sentinel Surveillance | 1 | 2013 | 12 | 0.100 |
Why?
|
| Benzazepines | 1 | 2013 | 24 | 0.100 |
Why?
|
| Prognosis | 1 | 2014 | 603 | 0.100 |
Why?
|
| Economics, Pharmaceutical | 1 | 2012 | 2 | 0.100 |
Why?
|
| Home Care Agencies | 1 | 2012 | 2 | 0.100 |
Why?
|
| Abscess | 1 | 2012 | 6 | 0.100 |
Why?
|
| Continental Population Groups | 1 | 2014 | 286 | 0.100 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2013 | 96 | 0.100 |
Why?
|
| Drug Costs | 1 | 2012 | 32 | 0.100 |
Why?
|
| Ethnic Groups | 1 | 2015 | 451 | 0.100 |
Why?
|
| Office Visits | 1 | 2012 | 73 | 0.100 |
Why?
|
| Smoking Cessation | 1 | 2013 | 154 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2012 | 170 | 0.090 |
Why?
|
| Risk Factors | 2 | 2014 | 3258 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 605 | 0.080 |
Why?
|
| United States Food and Drug Administration | 2 | 2013 | 32 | 0.080 |
Why?
|
| Time Factors | 1 | 2012 | 1039 | 0.080 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 338 | 0.070 |
Why?
|
| Hispanic Americans | 2 | 2019 | 375 | 0.060 |
Why?
|
| European Continental Ancestry Group | 2 | 2019 | 476 | 0.060 |
Why?
|
| Periodicals as Topic | 1 | 2004 | 14 | 0.050 |
Why?
|
| Texas | 1 | 2004 | 41 | 0.050 |
Why?
|
| Attitude | 1 | 2004 | 28 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2004 | 41 | 0.050 |
Why?
|
| African Americans | 2 | 2019 | 439 | 0.050 |
Why?
|
| Health Services Research | 1 | 2004 | 202 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 1151 | 0.050 |
Why?
|
| Markov Chains | 1 | 2020 | 22 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2004 | 1280 | 0.040 |
Why?
|
| Administration, Intravesical | 1 | 2019 | 2 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 298 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 79 | 0.040 |
Why?
|
| Natural Language Processing | 1 | 2020 | 60 | 0.040 |
Why?
|
| Cell Count | 1 | 2016 | 11 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 302 | 0.030 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2016 | 89 | 0.030 |
Why?
|
| Biomarkers | 1 | 2016 | 307 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 120 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 496 | 0.030 |
Why?
|
| Varenicline | 1 | 2013 | 12 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2016 | 1226 | 0.030 |
Why?
|
| Health Behavior | 1 | 2015 | 346 | 0.030 |
Why?
|
| Tobacco Use Disorder | 1 | 2013 | 36 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1098 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2013 | 146 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 840 | 0.020 |
Why?
|
| Medicaid | 1 | 2013 | 189 | 0.020 |
Why?
|
Concepts
(144)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(10)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->